GlassScriptPhysician profile
Janssen J Todd
NPI 1861954927
$3,897.39
in general payments reported to CMS, 2019-2025
44 companies · $2,545 in 2025
The $2,545 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $86.92 · 2023: $34.31 · 2024: $1,231 · 2025: $2,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425 · Education: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.61 |
| Education | $385.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $281.85 | 2023-2025 | Keytruda, Lynparza, Pifeltro |
| Janssen Biotech, INC. | $272.65 | 2024-2025 | Erleada, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $256.52 | 2024-2025 | Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $250.16 | 2024-2025 | Enhertu, Imfinzi |
| Pfizer INC. | $237.77 | 2024-2025 | |
| Celgene Corporation | $220.09 | 2024-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $218.47 | 2024-2025 | |
| Incyte Corporation | $180.78 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Abbvie INC. | $166.66 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $135.96 | 2024-2025 | Opdivo, Opdualag |
| Aveo Pharmaceuticals, INC. | $134.66 | 2024-2025 | |
| Lilly USA, LLC | $132.82 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $99.95 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.63 | 2024-2025 | Fruzaqla, Iclusig, Alunbrig |
| Astellas Pharma US INC | $92.14 | 2025 | Vyloy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janssen Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.